AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $28.21

AtriCure, Inc. (NASDAQ:ATRCGet Free Report)’s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $28.21 and last traded at $28.35, with a volume of 275503 shares trading hands. The stock had previously closed at $29.73.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ATRC. UBS Group boosted their price objective on AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Stifel Nicolaus dropped their price objective on AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. JMP Securities reissued a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research note on Wednesday, November 29th. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a research note on Tuesday, March 19th. Finally, Needham & Company LLC upped their price target on AtriCure from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.57.

Get Our Latest Stock Report on AtriCure

AtriCure Trading Down 4.2 %

The business has a 50 day moving average of $33.68 and a two-hundred day moving average of $36.55. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.66 and a current ratio of 3.57. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -43.14 and a beta of 1.39.

AtriCure (NASDAQ:ATRCGet Free Report) last issued its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $106.50 million during the quarter, compared to analyst estimates of $103.68 million. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) EPS. Equities analysts predict that AtriCure, Inc. will post -0.71 EPS for the current year.

Insiders Place Their Bets

In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the sale, the insider now directly owns 74,284 shares of the company’s stock, valued at approximately $2,727,708.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Karl S. Dahlquist sold 8,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $37.36, for a total value of $307,510.16. Following the completion of the transaction, the insider now directly owns 52,839 shares of the company’s stock, valued at $1,974,065.04. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total value of $55,080.00. Following the completion of the transaction, the insider now directly owns 74,284 shares of the company’s stock, valued at $2,727,708.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,616 shares of company stock valued at $423,212. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Institutional investors have recently modified their holdings of the business. CenterBook Partners LP bought a new position in shares of AtriCure in the third quarter valued at approximately $770,000. Envestnet Asset Management Inc. grew its holdings in AtriCure by 127.9% during the third quarter. Envestnet Asset Management Inc. now owns 116,990 shares of the medical device company’s stock valued at $5,124,000 after purchasing an additional 65,653 shares during the period. Decheng Capital Management III Cayman LLC bought a new position in AtriCure during the third quarter valued at $2,026,000. Silvercrest Asset Management Group LLC grew its holdings in AtriCure by 17.5% during the second quarter. Silvercrest Asset Management Group LLC now owns 251,386 shares of the medical device company’s stock valued at $12,408,000 after purchasing an additional 37,506 shares during the period. Finally, Tudor Investment Corp Et Al bought a new position in AtriCure during the third quarter valued at $3,838,000. 94.30% of the stock is owned by institutional investors.

About AtriCure

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Featured Articles

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.